NASDAQ:ARWR - Arrowhead Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $15.80 -0.61 (-3.72 %) (As of 07/16/2018 04:00 PM ET)Previous Close$16.41Today's Range$15.53 - $16.7652-Week Range$1.48 - $16.76Volume1.52 million shsAverage Volume1.84 million shsMarket Capitalization$1.44 billionP/E Ratio-33.64Dividend YieldN/ABeta2.5 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. Receive ARWR News and Ratings via Email Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:ARWR CUSIPN/A Webwww.arrowheadpharma.com Phone626-304-3400 Debt Debt-to-Equity Ratio0.02 Current Ratio10.16 Quick Ratio10.16 Price-To-Earnings Trailing P/E Ratio-33.64 Forward P/E Ratio-21.07 P/E GrowthN/A Sales & Book Value Annual Sales$31.41 million Price / Sales44.05 Cash FlowN/A Price / CashN/A Book Value$1.08 per share Price / Book14.63 Profitability EPS (Most Recent Fiscal Year)($0.47) Net Income$-34,380,000.00 Net Margins-199.55% Return on Equity-50.05% Return on Assets-40.83% Miscellaneous Employees93 Outstanding Shares87,580,000Market Cap$1,437.14 Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions What is Arrowhead Pharmaceuticals' stock symbol? Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR." How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) released its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company earned $0.65 million during the quarter, compared to the consensus estimate of $4.04 million. Arrowhead Pharmaceuticals had a negative return on equity of 50.05% and a negative net margin of 199.55%. View Arrowhead Pharmaceuticals' Earnings History. When is Arrowhead Pharmaceuticals' next earnings date? Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Arrowhead Pharmaceuticals. What price target have analysts set for ARWR? 6 brokers have issued 1 year price objectives for Arrowhead Pharmaceuticals' stock. Their predictions range from $4.00 to $17.00. On average, they expect Arrowhead Pharmaceuticals' share price to reach $11.9467 in the next twelve months. This suggests that the stock has a possible downside of 24.4%. View Analyst Ratings for Arrowhead Pharmaceuticals. What is the consensus analysts' recommendation for Arrowhead Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock? Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock: 1. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $13 PT for the completed enrollment of the Phase 1 trial of ARO-AAT for the treatment of Alpha-1 liver disease. We are encouraged by the impressive execution and rapid enrollment of 44 patients in approximately three months." (6/18/2018) 2. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018) Are investors shorting Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals saw a increase in short interest in June. As of June 29th, there was short interest totalling 11,521,857 shares, an increase of 54.2% from the June 15th total of 7,470,859 shares. Based on an average trading volume of 3,483,024 shares, the short-interest ratio is presently 3.3 days. Approximately 15.3% of the company's stock are short sold. View Arrowhead Pharmaceuticals' Current Options Chain. Who are some of Arrowhead Pharmaceuticals' key competitors? Some companies that are related to Arrowhead Pharmaceuticals include Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), Array Biopharma (ARRY) and OPKO Health (OPK). Who are Arrowhead Pharmaceuticals' key executives? Arrowhead Pharmaceuticals' management team includes the folowing people: Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 49)Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 52)Dr. Bruce D. Given, Chief Operating Officer (Age 64)Mr. Patrick O'Brien, Gen. Counsel (Age 54)Mr. Peter B. Leone MBA, VP of Strategic Bus. Initiatives (Age 61) Has Arrowhead Pharmaceuticals been receiving favorable news coverage? Media coverage about ARWR stock has been trending somewhat negative on Monday, according to Accern. The research firm identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arrowhead Pharmaceuticals earned a news impact score of -0.01 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 45.76 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include RTW INVESTMENTS, LP (5.02%) and Bank of Montreal Can (0.02%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Institutional Ownership Trends for Arrowhead Pharmaceuticals. Which major investors are selling Arrowhead Pharmaceuticals stock? ARWR stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Insider Buying and Selling for Arrowhead Pharmaceuticals. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Arrowhead Pharmaceuticals' stock price today? One share of ARWR stock can currently be purchased for approximately $15.81. How big of a company is Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals has a market capitalization of $1.44 billion and generates $31.41 million in revenue each year. The biotechnology company earns $-34,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Arrowhead Pharmaceuticals employs 93 workers across the globe. How can I contact Arrowhead Pharmaceuticals? Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected] MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 249 (Vote Outperform)Underperform Votes: 169 (Vote Underperform)Total Votes: 418MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: Should I follow buy, hold and sell recommendations?